Albiges L et al. Phase II KEYNOTE-B61 study of pembrolizumab (pembro) + lenvatinib (lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). ESMO 2022;Abstract 14480.
Allaf M et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. ESMO 2022;Abstract LBA67.
Atkins MB et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. J Clin Oncol 2022;40(6):186-97. Abstract
Atkins MB et al. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. ASCO GU 2022;Abstract 288.
Atkins MB et al. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 2022;40(25):2913-23. Abstract
Bex A et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. ESMO 2022;Abstract LBA66.
Chen Y-W et al. Emerging targets in clear cell renal cell carcinoma. Cancers Basel 2022;14(19):4843. Abstract
Choueiri TK et al. Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). ASCO GU 2023;Abstract 608
Choueiri TK et al. Nivolumab plus cabozantinib vs sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829-41. Abstract
Choueiri TK et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. ASCO GU 2022;Abstract 290.
Choueiri T et al. Phase III study of cabozantinib (c) in combination with nivolumab (n) and ipilimumab (i) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). ESMO 2022;Abstract LBA8.
Fay AP. Invited discussant 1447O and 1448O. ESMO 2022;Abstract discussant 14470 and 14480.
Jonasch E et al. Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up. ASCO 2022;Abstract 4509.
McCabe EM et al. Belzutifan (Welireg™) for von Hippel Lindau disease. Trends Pharmacol Sci 2022;43(10) :882-3. Abstract
Moch H et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours. Eur Urol 2022;82(5):458-68. Abstract
Motzer RJ et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial. Lancet 2023;[Online ahead of print]. Abstract
Motzer RJ et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128(11):2085-97. Abstract
Motzer RJ et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(7):888-98. Abstract
Powles T et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022 Sep;23(9):1133-44. Abstract
Powles T et al. TROPHU-U-01 cohort 5: Evaluation of maintenance sacituzumab govitecan (SG) plus zimberelimab (ZIM), ZIM, or avelumab in cisplatin-eligible patients (pts) with unresectable or metastatic urothelial cancer (mUC). ASCO GU 2022;Abstract TPS598.
Rini BI et al. Maturation of overall survival (OS) in TIVO-3 with long-term follow-up. ASCO 2022;Abstract 4557.
Rini BI et al. Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: Data from the phase III JAVELIN Renal 101 trial. J Clin Oncol 2022;40(17):1929-38. Abstract
Rini BI et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 2020;21(1):95-104. Abstract
Srinivasan R. Belzutifan for cancers associated with von Hippel-Lindau syndrome. ASCO 2022 Educational Session;Abstract.
Tykodi SS et al. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 2022;10(2):e003844. Abstract